Ventoux Biosciences

Ventoux Biosciences is a biopharmaceutical company focused on acquiring, in-licensing, developing, and commercializing proprietary products for Dupuytrens Disease and related fibroproliferative, inflammatory conditions with significant unmet medical need. Founded by a pharmaceutical industry executive who is also a Dupuytren’s patient, Ventoux Biosciences launched in 2022 with a goal of helping the millions of fellow patients with this under-served, debilitating, disease.